About us

Engineering an Evolution in Cancer Immunotherapy

Century Therapeutics is an innovative biotechnology

company utilizing a comprehensive cell therapy platform

to develop transformative allogeneic cell therapies with

the potential to overcome many of the challenges inherent

to cell therapy and provide a significant advantage over

existing cell therapy technologies.

OUR MISSION

We are leveraging our expertise in cellular reprogramming, 

genetic engineering, and manufacturing to evolve the way 

patients are treated with cell therapies and positively 

transform the lives of patients suffering from 

life-threatening cancers.

TEAM

We are led by pioneers and industry veterans with decades of collective manufacturing and commercialization experience bringing cell therapy products to market. Our board of directors includes members with extensive experience leading companies in the fields of biotechnology and biopharmaceuticals. Our internal abilities are further underpinned by our Scientific Advisory Board, which consists of world-renowned scientists, clinicians, and key opinion leaders with decades of experience in the fields of stem cell biology, immunology, oncology, and cell therapy.

MANAGEMENT TEAM

Osvaldo (Lalo) Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

Lalo Flores 2

Lalo Flores, PhD

CEO

Hy Levitsky is President of Research and Development at Century Therapeutics. He was previously Executive Vice President and Chief Scientific Officer at Juno Therapeutics in Seattle, and before that, Head of Cancer Immunotherapy Experimental Medicine at Roche Pharma Research and Early Development in Switzerland. He received an MD from Johns Hopkins University School of Medicine in 1984, followed by training in internal medicine and medical oncology. He joined the Johns Hopkins faculty in 1991, rising to Professor of Oncology, Medicine and Urology in 2001 while working at the Sidney Kimmel Comprehensive Cancer Center where he served as Scientific Director of the George Santos Bone Marrow Transplant Program. Upon joining industry, he has held an adjunct professorship since 2011. His research has focused on tumor immunology, cancer vaccines, and adoptive T cell therapy. He is a Leukemia and Lymphoma Society Stohlman Scholar, a Member of the American Society for Clinical Investigation, and is a founding member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Hy Levitsky n

Hy Levitsky, MD

President of Research & Development

Luis Borges is Chief Scientific Officer at Century Therapeutics. At Century, Luis oversees the research and clinical candidate selection of genetically engineered induced pluripotent stem cell (iPSC)-derived immune cell products to treat hematologic and solid tumors. Before joining Century, Luis developed a pipeline of novel CAR-celltherapies and managed a collaboration with the Baylor College of Medicine to develop allogeneic CAR-NKT cells at Cell Medica. Prior to joining Cell Medica, Luis served as SVP of Research at Five Prime Therapeutics, where he helped transition the company into cancer immunotherapy. In three years at Five Prime, Luis re-shaped and grew the research organization. His group transitioned three novel drug candidates from discovery into investigational new drug (IND)-enabling studies with two of them reaching the clinic. Before joining Five Prime, Luis led numerous drug development teams at Immunex and Amgen. He received his PhD from the University of Washington, Seattle.

Luis Borges n

Luis Borges, PhD

Chief Scientific Officer

Adrienne Farid is Century’s Chief Operations Officer. She joined Century from Celgene, where she was Corporate Vice President, Project Leadership and Business Operations in Research & Early Development. Her group ran early development teams, in the past few years filing >20 Investigational New Drug (IND)/Clinical Trial Applications (CTAs) and progressing numerous Phase 1/2 assets in hematology, oncology, and inflammation/immunology. Adrienne was co-lead of the global Liso-cel development team with Juno Therapeutics from 2015-2017, and as part of collaboration governance, she was instrumental in contributing to Celgene’s cell therapy strategies. She led Celgene’s integration of Juno Therapeutics in 2018. Earlier, Adrienne led global development teams, including Pomalyst® in relapsed/refractory multiple myeloma through registration. At Roche for 15 years, she advanced through technical and global development leadership. She began her career at SmithKline Beecham. Adrienne received her Ph.D. in Chemistry from Columbia University, followed by postdoctoral studies at California Institute of Technology.

Adrienne Farid 2

Adrienne Farid, PhD

Chief Operations Officer

Greg Russotti is the Chief Technology Officer at Century Therapeutics. Before joining Century, Greg was Vice President of Cell Therapy Development and Operations at Celgene. During his tenure there, he guided CMC efforts for five different cell therapy products to IND and clinical stage development. Greg was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgene’s first commercial CAR T manufacturing facility. Prior to Celgene, Greg held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. Greg received his BS and MS degrees in Chemical Engineering from Rensselaer Polytechnic Institute and his PhD in Chemical and Biochemical Engineering from Rutgers University. He has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. Greg also serves as Industrial Executive Board Chairman of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the NSF-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech.

Greg Rusotti

Greg Russotti, PhD

Chief Technology Officer

Michael Diem is Chief Business Officer at Century Therapeutics. Before joining Century, Mike was Senior Vice President of Business and Corporate Development at Amicus Therapeutics and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier in his career, he was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the company’s strategic investment activities and MedImmune Ventures. At GlaxoSmithKline, he led business development for the company’s rare disease business unit. He was also a partner in GSK’s corporate venture firm, SR One, Limited. Mike holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow. He currently serves as a board director at VenatoRx Pharmaceuticals and the Boys and Girls Clubs of Philadelphia.

Circle cropped

Michael Diem, MD

Chief Business Officer

Michael Naso is Vice President of Cell Engineering at Century Therapeutics, where he leads early discovery efforts to identify engineered cell therapy products for clinical development. Michael was a Director of Cell and Gene Therapy at Janssen Research and Development, leading Janssen’s first gene and cell therapy discovery group. In that role, he initiated Janssens first gene therapy programs utilizing rAAV technology and their first engineered cell therapy efforts toward an allogeneic, off-the-shelf platform. His time in that role led to the identification of novel tumor targeting technologies and engineered cell therapy platforms. While at Janssen and Centocor, he also played important discovery roles bringing numerous product candidates into early development and was part of the discovery teams that launched Remicade, Stelara, Simponi and Tremfya. Michael holds a Ph.D from Thomas Jefferson University in Biochemistry and Molecular Biology.

Michael Naso 2

Michael Naso, PhD

VP Cell Engineering

Carl Burke is Vice President of Development and Manufacturing at Century Therapeutics. Before joining Century, Carl developed and manufactured allogeneic and autologous cell therapies and their regulatory filings at Janssen. Carl started his career at Merck in 1990 responsible for protein and vaccine product development and involved analytical characterization, formulation and filling process development, technology transfer and marketed product support. This work contributed to the successful licensure and post-approval support of many vaccines. Carl joined Janssen in 2008 and initially led the drug product development area for biologics and parenterals. Afterwards, he moved to the Netherlands to lead the vaccines development in Janssen Vaccines, which included all CMC development activities and pilot plants. Upon returning to the US, Carl led the team integrating novel cell therapy process operations as they transitioned to manufacturing.

Carl Burke n

Carl Burke, PhD

VP Development & Manufacturing

Douglas Carr is Vice President of Finance and Operations at Century Therapeutics. Prior to joining Century, he was VP of Finance at Novira Therapeutics, Inc., where he directed all financial and fiscal management aspects of the Company’s operations and played a key role in the sale of the Company to J&J in December 2015. Before Novira, he was Financial Controller for Omthera Pharmaceuticals, Inc. where he established the finance and accounting infrastructure and led the Company through an initial public offering and subsequent sale to Astra Zeneca in 2013. Prior to Omthera, Douglas spent 15 years at Merck primarily providing financial leadership to various commercial franchises. He began his career at PriceWaterhouseCoopers (previously Coopers&Lybrand). Douglas holds a BA from Rutgers University and is a Certified Public Accountant in the State of New Jersey. He currently serves on the Board of Directors at Heritage Conservancy in Doylestown, Pennsylvania.

Douglas Carr 2

Douglas Carr, CPA

VP Finance & Operations

Shane Williams is Century Therapeutics’ Chief People Officer and is responsible for the talent agenda, culture, and HR systems. Prior to Century, Shane was the Head of HR Business Partners at QIAGEN, where he supported the Executive Committee on people-related topics. He and his team led global HR initiatives, including Diversity and Inclusion programs, competency mapping, annual compensation management, and the coordination of efficiency objectives. Before joining QIAGEN, Shane held positions with Boston Consulting Group (BCG) in an operational capacity, and with EgonZehnder where was a core member the management appraisal practice and conducted executive searches for global biopharmaceutical clients. Shane spent five years with Elan Pharmaceuticals, as the General manager of PRIALT (an innovative biologic for chronic pain) and in strategy leadership roles. He began his career as a consultant with BCG. Shane received his Ph.D. in Biochemistry from Cambridge University, followed by postdoctoral research at Harvard-MIT Health Sciences and Technology.

Shane Williams 2

Shane Williams, PhD

Chief People Officer

Ken Dow is Vice President, Law at Century Therapeutics. He was previously Vice President, Pharmaceutical Patent Strategy in the Johnson & Johnson Law Department where he was responsible for pre-litigation planning and strategy concerning the patent portfolio for the pharmaceutical sector. Before that he was Vice President, Patent Law at Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. At Janssen Biotech, Mr. Dow was a member of the research management board and was responsible for overseeing all patent matters for the oncology and immunology therapeutic areas, including patent opinions, litigation, preparation and prosecution, as well as licensing and transactional matters. Mr. Dow received his B.S. in Pharmacy from the State University of New York at Buffalo and his J.D. from St. John's University. Mr. Dow was recently the chair of the Biotechnology Innovation Organization IP Counsels Committee.

Ken Dow 3 2

Kenneth J. Dow, JD

VP, Law

Mark Wallet is Vice President, Head of Immunology at Century Therapeutics where he leads immunology research activities to help create the next generation of iPSC-derived cell therapy products for cancer. In this role, he leads multiple research teams (In Vitro Pharmacology, In Vivo Pharmacology, and Immunology) that strive to create the best possible therapeutic cells. Mark trained as an immunologist with a focus on how the immune system learns to tolerate self-antigens in the thymus and peripheral tissues . Mark began his post-education career as Assistant Professor at the University of Florida (UF) where his lab investigated the human immune system using induced pluripotent stem cell (iPSC)-derived immune cells and gene editing technologies. Working closely with the UF Center for Cellular Reprogramming, UF Diabetes Institute, and collaborators at AIST (Tsukuba, Japan), the Wallet lab establish methods to efficiently modify the genomes of iPSCs and then to differentiate modified cells into monocytes, macrophages and dendritic cells. This work focused on understanding how the human immune system is regulated in viral infections (HIV) and autoimmune diseases such as type 1 diabetes. Switching paths to cancer immunotherapy, Mark joined Fate Therapeutics where he helped establish the translational research strategies for iPSC-derived NK cell therapies. Mark holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill.

Mark W 2

Mark Wallet

VP Head of Immunology

Melody Eble is this Vice President of Regulatory Affairs at Century Therapeutics. Over the course of her career in the pharmaceutical industry, Melody has contributed to small and large molecule oncology drug development, led a regulatory intelligence team, and provided Global Regulatory project leadership for J&J’s allogeneic cell therapy/delivery system combination product as well as the Cross-Sector Global Regulatory cell and gene therapy policy efforts. Melody completed her B.S. and Doctor of Pharmacy degrees at the State University of New York at Buffalo and completed an ASHP Accredited Post-Doctoral Residency in Oncology Pharmacy in San Antonio, Texas.

Melody Small 2

Melody L. Eble, Pharma D

VP Regulatory Affairs

BOARD OF DIRECTORS

Osvaldo (Lalo) Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

Lalo Flores 2

Lalo Flores, PhD

CEO at Century Therapeutics

Carlo Rizzuto is a Partner with Versant Ventures and focuses on biotech investing and company building. Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup. Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.

Carlo Rizzuto 2

Carlo Rizzuto, PhD

Partner at Versant Ventures

Joe Jimenez is Co-Founder and Managing Partner at Aditum Bio, a biotech venture firm. From 2010 to 2018, Mr. Jimenez held the position of Chief Executive Officer (CEO) of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of self-originated drugs in the industry, driven by a strong commitment to R&D. Mr. Jimenez also transformed the company’s portfolio to focus on innovative patented medicines under Novartis Pharmaceuticals and Novartis Oncology, generics under Sandoz, and eye care devices under Alcon. Mr. Jimenez is currently a member of the Board of Directors of General Motors Company, The Proctor & Gamble Company, and Century Therapeutics. Additionally, he served on the Board of Directors of Colgate-Palmolive Company from 2009 to 2015, and of AstraZeneca PLC, from 2002 to 2007. He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley.

Joe Jimenez

Joe Jimenez, MBA

Co-Founder and Managing Partner at Aditum Bio

Eli Casdin founded Casdin Capital in 2011 after nearly ten years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine. Casdin Capital’s combination of long-term vision and strong industry relationships keep it focused on the big picture yet nimble, while maintaining a consistent approach: Take aim at big markets; Invest in great ideas and great teams; Stay focused; Avoid hubris.

Prior to founding Casdin Capital, Eli was a Vice President and Analyst at Alliance Bernstein and a member of its “thematic” based investment group, responsible for researching and investing in the implications of new technologies for the life science and healthcare sectors. Eli’s early experience includes time at Bear Stearns and at Cooper Hill Partners, one of the earliest biotechnology focused investment firms.

Eli earned his B.S. from Columbia University and his MBA from Columbia Business School and serves on the Columbia University School of GS Board of Directors.

Eli Casdin LG 2

Eli Casdin

Chief Investment Officer of Casdin Capital

Kimberly Blackwell is currently the Chief Medical Officer at Tempus Labs, a technology company compiling a library of clinical and molecular data to drive advances in precision medicine, and a scientific co-founder of Cereius Radiopharmaceuticals. Kimberly joined Tempus Labs from Eli Lilly where she served as Vice President of Early Phase Oncology and Immuno-oncology, driving clinical development of all pre-approval oncology agents. Before joining the biopharma sector, Kimberly was a Professor of Medicine and an Assistant Professor of Radiation of Oncology at Duke University Medical Center where she also led the Women’s Cancer Program, the Breast Cancer Program, and Strategic Relations initiatives. Kimberly holds a BA in Bioethics from Duke University and received her MD from the Mayo Clinic Medical School.

Kiimberly L Blackwell 1

Kimberly Blackwell, MD

CMO at Tempus Labs

Alessandro Riva was recently the Chief Executive Officer and a Board Member at Ichnos Sciences, a biotechnology company advancing bi/trispecific antibody cancer therapeutics and biologics targeting autoimmune diseases. Prior to joining Ichnos, Alessandro was the Executive Vice President and Global Head of Oncology Therapeutics and Cell Therapy at Gilead Sciences, where he led the company’s acquisition of Kite Pharma. Alessandro also served as the Executive Vice President Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals and was President ad interim of Novartis Oncology during the acquisition of GSK Oncology. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer and Aventis and co-founded the Breast Cancer International Research Group (BCIRG) and the Cancer International Research Group (CIRG). Alessandro received his BMBS and MD in Oncology/Hematology from the University of Milan.

Alessandro 1

Alessandro Riva, MD

Independent Director at Century Therapeutics

Cynthia was most recently the Chief Operating Officer and Chief Financial Officer of Kite Pharma where she was responsible for securing over $1B in capital and played a key role in facilitating the company’s acquisition by Gilead Sciences. Before Kite Pharma, Cynthia served as the Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals leading until its acquisition by Pfizer. Cynthia also held numerous executive leadership roles earlier in her career including Chief Operating Officer and Chief Financial Officer at Telik, Inc. as well as Vice President of Finance and Administration and Chief Financial Officer at Connetics Corporation. Cynthia earned her BS in Business and Accounting from Edgewood College and received her MBA in Finance from the University of Wisconsin, Madison.

Cynthia Butitta 1

Cynthia Butitta, MBA

Independent Director at Century Therapeutics, Autolus, UroGen and Olema

SCIENTIFIC ADVISORY BOARD

Dr. Greg Delgoffe studies the impact of the tumor microenvironment on T cell subsets that infiltrate the tumor. His research aims to dissect how tumor cells promote an immunosuppressive environment through the modulation of metabolism via interrogation from two major perspectives: Immunometalolism of tumor-infiltrating Treg cells and metabolic reprogramming of exhausted antitumor cytotoxic T lymphocytes.

Greg Delgoffe, PhD

Associate Professor, Department of Immunology, University of Pittsburgh Member, University of Pittsburgh Cancer Institute

Dr. Barbara Kee studies the transcriptional regulatory networks that control the development of innate and adaptive lymphoid cells and the mechanisms that control their homeostasis. Dr. Kee’s work is focused on basic helix-loop-helix transcription factors and ETS proteins to derive an understanding of

how these constructs operate in distinct cellular contexts in which they might promote similar or distinct gene programs.

Barbara Kee, PhD

Professor of Pathology, University of Chicago

Dr. Nakauchi is working at the intersection of immunology, cellular and molecular biology, developmental engineering and clinical medicine to uncover new diseases, elucidate the causes of disease and develop novel therapeutic modalities. His research is focused on elucidation of heterogeneity and hierarchy in hematopoietic stem cells, rejuvenation of antigen specific T cells for efficient immunotherapy and generation of organs from iPSC by way of blastocyst complementation.

Hiromitsu (Hiro) Nakauchi, MD, PhD

Professor, Department of Genetics, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

Dr. Ellen Rothenberg studies the molecular mechanisms that are responsible for developmental lineage choice as hematopoietic stem cells differentiate into T lymphocytes. Her work is focused on identifying the transcription factors and signaling events that induce T-lineage gene expression in an uncommitted precursor and determining how they work to force the cell to relinquish other developmental options.

Ellen Rothenberg, PhD

Albert Billings Ruddock Professor of Biology, California Institute of Technology

Dr. Cameron Turtle studies how immune T cells can be engineered to fight hematologic malignancies. His laboratory in the Clinical Research Division at Fred Hutch has extensive expertise in the genetic modification and analysis of T cells, and he leads several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies for patients with B-cell malignancies. By studying the reasons for success and failure of T cell therapies in patients treated on their clinical trials, the team takes a rational approach to improving treatment of patients with cancer.

Cameron (Cam) Turtle, PhD

Associate Professor, Clinical Research Division, Fred Hutch
Anderson Family Endowed Chair for Immunotherapy, Fred Hutch
Associate Professor, Department of Medicine, University of Washington

Partners

© Century Therapeutics 2021 | Legal